Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002372 · ClinicalTrials.gov registry record · Phase 1
A Study of 141W94 in Combination With Other Anti-HIV Drugs
A Phase 1 study of HIV Infections, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 3
- Study locations
NCT00002372: Completed Phase 1 study of HIV Infections, sponsored by Glaxo Wellcome.
NCT00002372 is a Phase 1 study of HIV Infections that has completed, run by Glaxo Wellcome. The registered enrollment target is 48 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (89% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002372, a Phase 1 study of HIV Infections, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 3
- Study locations
Study Summary
To determine the steady-state pharmacokinetics of 141W94 in combination with saquinavir, indinavir and nelfinavir after multiple oral dosing. To determine the steady-state pharmacokinetics of saquinavir, indinavir, and nelfinavir in combination with 141W94 after multiple oral dosing. To assess the safety and tolerability of multiple doses of 141W94 when combined with saquinavir, indinavir and nelfinavir.
Conditions Studied
Interventions
- DRUG Indinavir sulfate
- DRUG Nelfinavir mesylate
- DRUG Saquinavir
- DRUG Amprenavir
Study Locations (3)
California
- Univ of California / San Diego Treatment Ctr - San Diego
- ViRx Inc - San Francisco
North Carolina
- Univ of North Carolina at Chapel Hill / Duke Univ Med Ctr - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Phase | Phase 1 |
What the finished NCT00002372 record still lists
NCT00002372 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (89% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 4 interventions - of which Indinavir sulfate is the first listed.
NCT00002372 reports a single indexed study location in California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00002372 about?
NCT00002372 is a clinical study titled "A Study of 141W94 in Combination With Other Anti-HIV Drugs". To determine the steady-state pharmacokinetics of 141W94 in combination with saquinavir, indinavir and nelfinavir after multiple oral dosing. To determine the steady-state pharmacokinetics of saquinavir, indinavir, and nelfinavir in combination with 141W94 after multiple oral dosing. To assess the s...
What is the current status of trial NCT00002372?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants.
What conditions does trial NCT00002372 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002372?
The interventions under investigation include: Indinavir sulfate (DRUG), Nelfinavir mesylate (DRUG), Saquinavir (DRUG), Amprenavir (DRUG).
Who is sponsoring clinical trial NCT00002372?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002372 being conducted?
This trial has 3 study locations across California, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00002372's enrollment target sits among peer trials
48 367th of 542 higher than 168 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention